Source:http://linkedlifedata.com/resource/pubmed/id/19375474
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
8
|
| pubmed:dateCreated |
2009-8-11
|
| pubmed:abstractText |
Since new technologies based on solid phase assays (SPA) have been routinely incorporated in the transplant immunology laboratory, the presence of pretransplantation donor-specific antibodies (DSA) against human leukocyte antigen (HLA) molecules has generally been considered as a risk factor for acute rejection (AR) and, in particular, for acute humoral rejection (AHR). We retrospectively studied 113 kidney transplant recipients who had negative prospective T-cell and B-cell complement-dependent cytotoxicity (CDC) crossmatches at the time of transplant. Pretransplantation sera were screened for the presence of circulating anti-HLA antibody and DSA by using highly sensitive and HLA-specific Luminex assay, and the results were correlated with AR and AHR posttransplantation. We found that approximately half of our patient population (55/113, 48.7%) had circulating anti-HLA antibody pretransplantation. Of 113 patients, 11 (9.7%) had HLA-DSA. Of 11 rejection episodes post-transplant, only two patients had pretransplantation DSA, of whom one had a severe AHR (C4d positive). One-year allograft survival was similar between the pretransplantation DSA-positive and -negative groups. Number, class, and intensity of pretransplantation DSA, as well as presensitizing events, could not predict AR. We conclude that, based on the presence of pretransplantation DSA, post-transplantation acute rejections episodes could not have been predicted. The only AHR episode occurred in a recipient with pretransplantation DSA. More work should be performed to better delineate the precise clinical significance of detecting low titers of DSA before transplantation.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1879-1166
|
| pubmed:author | |
| pubmed:issnType |
Electronic
|
| pubmed:volume |
70
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
580-3
|
| pubmed:meshHeading |
pubmed-meshheading:19375474-Adolescent,
pubmed-meshheading:19375474-Adult,
pubmed-meshheading:19375474-Aged,
pubmed-meshheading:19375474-Antibody Formation,
pubmed-meshheading:19375474-Child,
pubmed-meshheading:19375474-Child, Preschool,
pubmed-meshheading:19375474-Female,
pubmed-meshheading:19375474-Graft Rejection,
pubmed-meshheading:19375474-HLA Antigens,
pubmed-meshheading:19375474-Humans,
pubmed-meshheading:19375474-Immunosorbent Techniques,
pubmed-meshheading:19375474-Isoantibodies,
pubmed-meshheading:19375474-Kidney Transplantation,
pubmed-meshheading:19375474-Male,
pubmed-meshheading:19375474-Microspheres,
pubmed-meshheading:19375474-Middle Aged,
pubmed-meshheading:19375474-Predictive Value of Tests,
pubmed-meshheading:19375474-Prognosis,
pubmed-meshheading:19375474-Retrospective Studies,
pubmed-meshheading:19375474-Risk Factors,
pubmed-meshheading:19375474-Transplantation Immunology
|
| pubmed:year |
2009
|
| pubmed:articleTitle |
Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant.
|
| pubmed:affiliation |
Service of Immunology and Allergy, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland. vincent.aubert@chuv.ch
|
| pubmed:publicationType |
Journal Article
|